ABSTRACT
Objective: Severe cutaneous adverse reactions (SCARs) are rare but life-threatening, with antibiotics being the main cause. This retrospective study from a single center was designed to analyze the culprit drugs, clinical features and treatment outcomes of antibiotic-induced SCARs. Methods: We analyzed cases of antibiotic-induced SCARs in a tertiary hospital in China between January 2013 and January 2024, including Steven-Johnson syndrome (SJS) or Stevens-Johnson syndrome-toxic epidermal necrolysis (SJS-TEN) overlap, toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS) and acute generalized exanthematous pustulosis (AGEP). Descriptive analysis of the demographic characteristics, clinical manifestations, treatment and prognosis were carried out. Results: Among 354 cases of SCARs, 63 validated antibiotic-related cases were included. Cephalosporins (31.7%), penicillins (25.4%), and quinolones (19.0%) were the most common triggers for SCARs. Overall, liver (50.8%), lungs (31.7%), and kidneys (23.8%) were the most frequently affected organ in SCARs cases. Eight patients (28.6%) in the SJS/SJS-TEN overlap group and 8 patients (80.0%) in the TEN group received combination therapy of corticosteroids and IVIG. Patients with SCARs caused by penicillins or cephalosporins could receive alternative treatments such as lincomamides, quinolones, and tetracyclines. The mortality rate in the TEN group was the highest at 20.0%, followed by the SJS/SJS-TEN overlap group (7.1%), and no deaths were observed in the DRESS and AGEP groups. Conclusion: The identification of the culprit antibiotics and the application of alternative antibiotic therapies are crucial for the management of antibiotic-induced SCARs. If complicated underlying conditions and complications like advanced age, cancer and pneumonia coexist with SCARs, patients might be more at risk for mortality.
Subject(s)
Anti-Bacterial Agents , Humans , Retrospective Studies , Male , Female , Anti-Bacterial Agents/adverse effects , Middle Aged , Adult , Aged , Stevens-Johnson Syndrome/etiology , Stevens-Johnson Syndrome/mortality , Stevens-Johnson Syndrome/drug therapy , Young Adult , China/epidemiology , Adolescent , Drug Hypersensitivity Syndrome/etiologySubject(s)
Drug Hypersensitivity Syndrome , Herpesvirus 6, Human , Lymphadenitis , Lymphoma , Roseolovirus Infections , Humans , Herpesvirus 6, Human/isolation & purification , Lymphadenitis/virology , Lymphadenitis/diagnosis , Lymphadenitis/etiology , Roseolovirus Infections/complications , Roseolovirus Infections/diagnosis , Drug Hypersensitivity Syndrome/diagnosis , Drug Hypersensitivity Syndrome/etiology , Drug Hypersensitivity Syndrome/pathology , Lymphoma/complications , Diagnosis, Differential , Male , Female , Middle AgedABSTRACT
BACKGROUND: There are limited data on severe cutaneous adverse reactions (SCARs) associated with antiepileptic medications. The current study aims to investigate the clinical and epidemiological characteristics of antiepileptic medication-induced SCARs in hospitalized children. MATERIALS AND METHODS: The current five-year retrospective study was conducted at Isfahan University of Medical Sciences, Iran. This study included all children with a definite diagnosis of SCARs secondary to the use of antiepileptic medications based on the world health organization (WHO) definition. In our study SCARs were categorized into three fields: Hypersensitivity syndrome, drug reaction with eosinophilia and systemic symptoms (DRESS), and Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN). RESULTS: Among 259 children with SCARs induced by antiepileptic medications, 199 (76.83%), 42 (16.22%), and 18 (6.95%) had hypersensitivity syndrome, DRESS, and SJS/TEN, respectively. Phenobarbital was the most common offending drug in all types of SCARs. The multinomial logistic regression model revealed that lymphadenopathy increased the occurrence of DRESS by 35 times compared to hypersensitivity syndrome (P < 0.001). Girls were at risk of SJS/TEN approximately 6 times more than boys (P = 0.027). Age (P = 0.021), weight (P = 0.036), and mucosal involvement (P < 0.001) affected the hospitalization duration in children with SCARs related to antiepileptic medication. CONCLUSION: There are some similarities and differences in the clinical and epidemiological features of Iranian children suffering from antiepileptic medication-induced SCARs.
Subject(s)
Anticonvulsants , Stevens-Johnson Syndrome , Humans , Anticonvulsants/adverse effects , Female , Male , Child , Retrospective Studies , Child, Preschool , Iran/epidemiology , Stevens-Johnson Syndrome/epidemiology , Stevens-Johnson Syndrome/etiology , Drug Hypersensitivity Syndrome/epidemiology , Drug Hypersensitivity Syndrome/etiology , Drug Hypersensitivity Syndrome/diagnosis , Adolescent , Infant , Child, Hospitalized , Hospitalization/statistics & numerical data , Risk FactorsSubject(s)
Drug Hypersensitivity Syndrome , Herpesvirus 6, Human , Roseolovirus Infections , Virus Activation , Humans , Herpesvirus 6, Human/isolation & purification , Roseolovirus Infections/diagnosis , Roseolovirus Infections/complications , Drug Hypersensitivity Syndrome/diagnosis , Drug Hypersensitivity Syndrome/etiology , Drug Hypersensitivity Syndrome/virology , Drug Eruptions/etiology , Drug Eruptions/diagnosis , Eosinophilia/chemically induced , Eosinophilia/virology , Eosinophilia/diagnosis , Latent InfectionABSTRACT
This cohort study examines patients with drug reaction with eosinophilia and systemic symptoms who also have pustules.
Subject(s)
Drug Hypersensitivity Syndrome , Humans , Drug Hypersensitivity Syndrome/diagnosis , Drug Hypersensitivity Syndrome/etiology , Male , Female , Middle Aged , Eosinophilia/chemically induced , Eosinophilia/diagnosisABSTRACT
Drug reaction with eosinophilia and systemic symptoms (DReSS) is known to cause mortality and long-term sequelae in the pediatric population, however there are no established clinical practice guidelines for the management of pediatric DReSS. We conducted a scoping review, according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, to summarize the currently available data on treatment, mortality, and long-term sequelae of DReSS in children (aged 0-18 years). Data from 644 individuals revealed that various treatment strategies are being used in the management of pediatric DReSS, and strategies were often used in combination. The diversity in treatment approaches cannot be solely attributed to age or disease severity and reflects the lack of evidence-based management guidelines for DReSS. Children are also at risk of developing autoimmune sequelae following DReSS, most commonly thyroid disease and type 1 diabetes mellitus. We found that the eventual development of autoimmune disease was more often associated with DReSS caused by antibiotics, especially minocycline and sulfamethoxazole, in comparison with individuals who did not develop sequelae. In this study, we identify strengths and weaknesses in the currently available literature and highlight that future prospective studies with structured and long-term follow-up of children with DReSS are needed to better understand potential risk factors for mortality and development of sequelae after DReSS.
Subject(s)
Drug Hypersensitivity Syndrome , Humans , Drug Hypersensitivity Syndrome/etiology , Drug Hypersensitivity Syndrome/diagnosis , Drug Hypersensitivity Syndrome/therapy , Child , Adolescent , Child, Preschool , Infant , Risk Factors , Anti-Bacterial Agents/adverse effects , Treatment Outcome , Autoimmune Diseases/chemically induced , Severity of Illness IndexSubject(s)
Drug Hypersensitivity Syndrome , Herpesvirus 6, Human , Roseolovirus Infections , Virus Activation , Female , Humans , Male , Middle Aged , Drug Eruptions/etiology , Drug Eruptions/diagnosis , Drug Hypersensitivity Syndrome/diagnosis , Drug Hypersensitivity Syndrome/etiology , Drug Hypersensitivity Syndrome/virology , Eosinophilia/chemically induced , Eosinophilia/diagnosis , Eosinophilia/virology , Herpesvirus 6, Human/isolation & purification , Latent Infection , Roseolovirus Infections/diagnosis , Roseolovirus Infections/complicationsABSTRACT
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) is characterized by a widespread maculopapular rash, lymphadenopathy, fever, and multisystem involvement. Conversely, hemophagocytic lymphohistiocytosis (HLH) is an infrequent yet critical condition presenting with fever, hepatosplenomegaly, cytopenias, coagulation abnormalities, and elevated inflammatory markers. The overlapping clinical and laboratory features between DRESS and HLH poses a significant diagnostic challenge. Secondary HLH (sHLH) typically occurs in adults triggered by viral infections, malignancies, rheumatologic diseases, or immune deficiencies. Recently, COVID-19 has also been identified as one of the triggers for sHLH. Herein, we present a case of Sulfasalazine-induced DRESS coinfected with COVID-19 that subsequently progressed into HLH. Our patient exhibited common hepatorenal and splenic involvement along with rare cholecystitis and appendicitis. However, a significant improvement was observed upon the addition of etoposide and azathioprine. We hypothesize that excessive activation of the immune system and cytokine storm due to DRESS combined with COVID-19 infection led to more extensive systemic damage resulting in HLH development. This highlights the potential for severe consequences when DRESS coincides with HLH during a COVID-19 infection.
Subject(s)
COVID-19 , Coinfection , Drug Hypersensitivity Syndrome , Lymphohistiocytosis, Hemophagocytic , SARS-CoV-2 , Sulfasalazine , Humans , Lymphohistiocytosis, Hemophagocytic/etiology , Lymphohistiocytosis, Hemophagocytic/diagnosis , Lymphohistiocytosis, Hemophagocytic/drug therapy , COVID-19/complications , COVID-19/immunology , Drug Hypersensitivity Syndrome/etiology , Drug Hypersensitivity Syndrome/diagnosis , Sulfasalazine/adverse effects , Coinfection/drug therapy , Male , Middle Aged , FemaleABSTRACT
BACKGROUND/OBJECTIVES: The immune checkpoint inhibitors (ICIs) have been increasingly associated with severe cutaneous adverse reactions (SCARs). These reactions, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS) and acute generalized exanthematous pustulosis (AGEP) are uncommon but potentially lethal. Despite the severity of these reactions and growing association with the ICIs, their specific risk and mortality rates have been largely unexplored. METHODS: A case/non-case analysis was performed using data from the United States Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) to examine the reporting odds ratios (RORs) for ICI-associated SCARs cases under two conditions: (1) ICIs compared with all drugs in FAERS and (2) ICIs compared with a reference group of pooled anticancer drugs to control for underlying malignancy. RESULTS: A statistically significant ROR for SJS (ROR: 5.44), TEN (ROR: 5.81) and DRESS (ROR: 1.38) were identified under Condition 1. Under Condition 2, this significance was maintained for SJS (ROR: 7.31), TEN (ROR: 7.40) and DRESS (ROR: 3.90), and mild significance was identified for AGEP (ROR: 1.89). Mortality rates for the ICIs were increased compared with the anticancer medications (28.5% vs. 24.5% for SJS, 55.3% vs. 46% for TEN, 3.0% vs. 2.1% for AGEP and 7.1% vs. 6.1% for DRESS). CONCLUSIONS: Our results suggest an association between SCARs and the ICIs independent of cancer status.
Subject(s)
Adverse Drug Reaction Reporting Systems , Immune Checkpoint Inhibitors , Stevens-Johnson Syndrome , United States Food and Drug Administration , Humans , Immune Checkpoint Inhibitors/adverse effects , Adverse Drug Reaction Reporting Systems/statistics & numerical data , United States , Stevens-Johnson Syndrome/etiology , Drug Eruptions/etiology , Female , Male , Drug Hypersensitivity Syndrome/etiology , Middle Aged , Acute Generalized Exanthematous Pustulosis/etiology , AgedABSTRACT
Severe cutaneous adverse reactions (SCARs), which include Stevens-Johnson syndrome and toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (also known as drug-induced hypersensitivity syndrome), acute generalized exanthematous pustulosis, and generalized bullous fixed drug eruption, are life-threatening conditions. The pathogenesis of SCARs involves T cell receptors recognizing drug antigens presented by human leukocyte antigens, triggering the activation of distinct T cell subsets. These cells interact with keratinocytes and various immune cells, orchestrating cutaneous lesions and systemic manifestations. Genetic predisposition, impaired drug metabolism, viral reactivation or infections, and heterologous immunity influence SCAR development and clinical presentation. Specific genetic associations with distinct SCAR phenotypes have been identified, leading to the implementation of genetic screening before prescription in various countries to prevent SCARs. Whilst systemic corticosteroids and conventional immunomodulators have been the primary therapeutic agents, evolving strategies, including biologics and small molecules targeting tumour necrosis factor, different cytokines, or Janus kinase signalling pathways, signify a shift towards a precision management paradigm that considers individual clinical presentations.
Subject(s)
Stevens-Johnson Syndrome , Humans , Stevens-Johnson Syndrome/physiopathology , Stevens-Johnson Syndrome/diagnosis , Stevens-Johnson Syndrome/etiology , Drug Hypersensitivity Syndrome/diagnosis , Drug Hypersensitivity Syndrome/physiopathology , Drug Hypersensitivity Syndrome/etiology , Drug Eruptions/physiopathology , Drug Eruptions/diagnosis , Drug Eruptions/etiology , Acute Generalized Exanthematous Pustulosis/diagnosis , Acute Generalized Exanthematous Pustulosis/etiology , Acute Generalized Exanthematous Pustulosis/physiopathologySubject(s)
Anticonvulsants , Drug Hypersensitivity Syndrome , Lamotrigine , Levetiracetam , Humans , Levetiracetam/adverse effects , Levetiracetam/therapeutic use , Lamotrigine/adverse effects , Lamotrigine/therapeutic use , Drug Hypersensitivity Syndrome/etiology , Drug Hypersensitivity Syndrome/diagnosis , Anticonvulsants/adverse effects , Female , Piracetam/analogs & derivatives , Piracetam/adverse effects , Piracetam/therapeutic use , Triazines/adverse effects , AdultABSTRACT
Effective treatment of drug reactions with eosinophilia and systemic symptoms (DReSS) requires early diagnosis and close monitoring. Diagnosing DReSS is especially challenging in children due to a low incidence rate, heterogeneous clinical presentation, and a lack of (pediatric) diagnostic criteria and clinical practice guidelines. We performed a scoping review, according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, to summarize the clinical presentation and diagnostic process of DReSS in children (aged 0-18 years). Data from 644 individuals showed that DReSS manifests differently in children compared to adults. Children have a higher number of organs involved, including higher rates of cardiac and respiratory involvement compared to adults. Children < 6 years of age appear more prone to develop neurologic symptoms. Conversely, eosinophilia, edema, and kidney involvement are less frequently observed in children. Anti-seizure medications are by far the most common causative drug class, but the range of implicated drugs increases as children get older. This study highlights that children with DReSS not only differ from adults but also that differences exist between children of different ages. As such, there is a need to establish pediatric-specific diagnostic criteria. These efforts will promote earlier diagnosis of DReSS and likely lead to improved clinical care offered to children and their families.
Subject(s)
Drug Hypersensitivity Syndrome , Humans , Child , Drug Hypersensitivity Syndrome/diagnosis , Drug Hypersensitivity Syndrome/etiology , Adolescent , Child, Preschool , Infant , Infant, Newborn , Age FactorsSubject(s)
Anticonvulsants , Clobazam , Drug Hypersensitivity Syndrome , Levetiracetam , Humans , Levetiracetam/adverse effects , Levetiracetam/therapeutic use , Drug Hypersensitivity Syndrome/epidemiology , Drug Hypersensitivity Syndrome/etiology , Drug Hypersensitivity Syndrome/diagnosis , Clobazam/adverse effects , Anticonvulsants/adverse effects , Incidence , Benzodiazepines/adverse effects , Piracetam/analogs & derivatives , Piracetam/adverse effects , Piracetam/therapeutic use , Female , Male , Middle Aged , Drug Hypersensitivity/epidemiology , AdultABSTRACT
ABSTRACT: Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is rare but carries significant mortality and morbidity, making early identification and definitive management crucial. The diagnosis of DRESS is made clinically and involves consideration of a broad list of differential diagnoses. Given variable clinical presentations among patients with DRESS syndrome, clinicians should look for common findings and other hallmarks of the syndrome while monitoring for known complications. Additionally, clinicians should maintain a high index of suspicion to avoid missing more mild presentations, such as in this case patient with DRESS syndrome minor.
Subject(s)
Drug Hypersensitivity Syndrome , Eosinophilia , Exanthema , Humans , Drug Hypersensitivity Syndrome/diagnosis , Drug Hypersensitivity Syndrome/etiology , Eosinophilia/chemically induced , Eosinophilia/diagnosis , Eosinophilia/complications , Exanthema/etiologyABSTRACT
Hydroxychloroquine is used for treatment of inflammatory diseases. It is considered to have few adverse effects. We report on a woman who developed a severe skin rash after intake of hydroxychloroquine, which she received for treatment of her lichen planopilaris. Based on the clinical, laboratory and histological findings the diagnosis of a drug reaction with eosinophilia and systemic symptoms (DRESS)-like drug reaction was established. Our case illustrates that hydroxychloroquine can lead to severe adverse effects in rare cases and that patients receiving this drug must be thoroughly informed.
Subject(s)
Hydroxychloroquine , Off-Label Use , Humans , Hydroxychloroquine/adverse effects , Hydroxychloroquine/therapeutic use , Hydroxychloroquine/administration & dosage , Female , Drug Hypersensitivity Syndrome/etiology , Drug Hypersensitivity Syndrome/diagnosis , Drug Hypersensitivity Syndrome/drug therapy , Lichen Planus/drug therapy , Lichen Planus/chemically induced , Lichen Planus/pathology , Middle Aged , Drug Eruptions/etiology , Drug Eruptions/diagnosis , Drug Eruptions/pathology , Drug Eruptions/drug therapyABSTRACT
BACKGROUND Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a rare hypersensitivity reaction involving the skin and various visceral organs; the kidneys are the second most affected organ. Many drugs are reported to be associated with DRESS, particularly antiepileptic agents and allopurinol. Certain human leukocyte antigen (HLA) haplotypes, in combination with a particular drug, can further contribute to an increased risk of DRESS. Symptoms often develop 2 to 8 weeks after drug initiation. If diagnosis is delayed, DRESS can be a life-threatening condition. CASE REPORT We present cases of 2 patients. The first patient was an 86-year-old Polish woman who developed acute kidney injury and skin lesions with accompanying leucocytosis and eosinophilia during long-term antibiotic therapy with piperacillin/tazobactam and ciprofloxacin. The second patient was a 37-year-old Asian woman with predialysis chronic renal disease stage V in the course of IgA nephropathy. Two weeks after starting allopurinol in a standard dose, she presented with maculopapular rash, facial edema, fever, liver injury, and eosinophilia. Renal function started to deteriorate, but she did not require dialysis. In both cases, the discontinuation of the above-mentioned drugs and the introduction of steroid therapy and intravenous immunoglobulins allowed for clinical improvement and recovery. In the second case, the extended 4-locus HLA typing was performed retrospectively, and allele HLA-B*5801 was found. CONCLUSIONS Due to the rare occurrence and heterogeneous manifestation of DRESS, its diagnosis can pose many difficulties. In-depth analysis of symptoms, medicines taken, and laboratory findings enable the implementation of appropriate treatment and recovery.